Back

dr. J.A.N. (Jannick) Dorresteijn

dr. J.A.N. (Jannick) Dorresteijn

Associate Professor - medical

Show full profile

Research Output (81)

The prediction of therapy-benefit for individual cardiovascular disease prevention:rationale, implications, and implementation

Jaspers Nicole E.M., Ridker Paul M., Dorresteijn Jannick A.N., Visseren Frank L.J. 1 Dec 2018, In: Current opinion in lipidology. 29 , p. 436-444 9 p.

Cholesterolverlaging bij ouderen

Kleipool Emma E.F., Dorresteijn Jannick A.N., Visseren Frank L.J., Hollander Monika, Peters Mike J.L., Muller Majon 5 Oct 2018, In: Nederlands Tijdschrift voor Geneeskunde. 162

Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease

Kaasenbrood Lotte, Ray Kausik K., Boekholdt S. Matthijs, Smulders Yvo M., LaRosa John C., Kastelein John J.P., Van Der Graaf Yolanda, Dorresteijn Johannes A.N., Visseren Frank L.J. 1 Oct 2018, In: Heart. 104 , p. 1699-1705 7 p.

Routinely measured hematological parameters and prediction of recurrent vascular events in patients with clinically manifest vascular disease

Kofink Daniel, Muller Steven A., Patel Riyaz S., Dorresteijn Jannick A.N., Berkelmans Gijs F.N., De Groot Mark C.H., Van Solinge Wouter W., Haitjema Saskia, Leiner Tim, Visseren Frank L.J., Hoefer Imo E., Asselbergs Folkert W., 1 Sep 2018, In: PLoS ONE [E]. 13

Estimated life expectancy without recurrent cardiovascular events in patients with vascular disease:The SMART-REACH model

Kaasenbrood Lotte, Bhatt Deepak L., Dorresteijn Jannick A.N., Wilson Peter W.F., D’Agostino Ralph B., Massaro Joseph M., van der Graaf Yolanda, Cramer Maarten J.M., Kappelle L. Jaap, de Borst Gert J., Steg Ph Gabriel, Visseren Frank L.J. 1 Aug 2018, In: Journal of the American Heart Association. 7

Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications:A cross-sectional study of patient and primary care physician perspectives

Jaspers Nicole E.M., Visseren Frank L.J., Numans Mattijs E., Smulders Yvo M., Van Loenen Martinet Fere A., Van Der Graaf Yolanda, Dorresteijn Jannick A.N. 1 May 2018, In: BMJ Open. 8

Decline in risk of recurrent cardiovascular events in the period 1996 to 2014 partly explained by better treatment of risk factors and less subclinical atherosclerosis

Berkelmans Gijs F N, van der Graaf Yolanda, Dorresteijn Jannick A.N., de Borst Gert Jan, Cramer Maarten J., Kappelle L. Jaap, Westerink Jan, Visseren Frank L.J., 15 Jan 2018, In: International Journal of Cardiology. 251 , p. 96-102 7 p.

A new selection method to increase the health benefits of CVD prevention strategies

Lagerweij Ghizelda R, de Wit G Ardine, Moons Karel Gm, van der Schouw Yvonne T, Verschuren Wm Monique, Dorresteijn Jannick An, Koffijberg Hendrik, 1 Jan 2018, In: European Journal of Preventive Cardiology. 25 , p. 642-650 9 p.

Relation between adiposity and vascular events, malignancy and mortality in patients with stable cerebrovascular disease

Jaspers N. E.M., Dorresteijn J. A.N., Van Der Graaf Y., Westerink J., Kappelle L. J., Nathoe H. M., Algra A., Visseren F. L.J. 1 Dec 2017, In: International Journal of Obesity. 41 , p. 1775-1781 7 p.

Identifying treatment response to antihypertensives in patients with obesity-related hypertension

Schrover Ilse M, Dorresteijn Jannick A N, Smits Jodine E, Danser A H Jan, Visseren Frank L J, Spiering Wilko Oct 2017, In: Clinical and experimental hypertension. Part A, Theory and practice. 23

Thank you for your review!

Has this information helped you?

Please tell us why, so that we can improve our website.

Working at UMC Utrecht

Contact

Emergency?

Directions

Appointments

Practical

umcutrecht.nl uses cookies

This website uses cookies This website displays videos from, among others, YouTube. Such parties place cookies (third-party cookies). If you do not want these cookies, you can indicate that here. We also place cookies ourselves to improve our site.

Read more about the cookie policy

Agree No, rather not